The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis

Diabetes, Obesity and Metabolism

Volumn 21, Issue 4, 2019, Pages 1018-1026

  Wang, Chen ^a   Zhou, Yue ^a   Kong, Zili ^a   Wang, Xiang ^a   Lv, Wenshan ^a   Geng, Zhuang ^a   Wang, Yangang ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ACUTE KIDNEY FAILURE; AGE; ALBUMINURIA; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL OUTCOME; DEATH; DIABETIC PATIENT; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FRACTURE; GENITAL TRACT INFECTION; GLUCOSURIA; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; INFECTION RISK; KIDNEY DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENAL REPLACEMENT THERAPY-DEPENDENT RENAL DISEASE; RISK REDUCTION; SYSTEMATIC REVIEW; TRAUMATIC AMPUTATION; TREATMENT DURATION; URINARY TRACT INFECTION; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; METABOLISM; MORTALITY; URINE;

ALBUMINURIA; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MORTALITY; RENAL REPLACEMENT THERAPY; REPRODUCTIVE TRACT INFECTIONS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85060164532     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13620     Document Type: Article

References (49)

1. Ghaderian SB, Hayati F, Shayanpour S, Beladi Mousavi SS. Diabetes and end-stage renal disease; a review article on new concepts. J Renal Inj Prev 2015;4:28-33.
2. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850-886.
3. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83:517-523.
4. Nair S, Wilding JPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34-42.
5. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63-71.
6. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6:6.
7. Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12:265-283.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
9. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
10. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539.
11. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013;11:43.
12. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384.
13. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159-169.
14. Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59:2036-2039.
15. Fioretto P, Del Prato S, Buse J, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study. Diabetes Obes Metab. 2018;20:2532-2540.
16. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396-3404.
17. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650-1659.
18. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597.
19. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15:1501-1515.
20. Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase ii trial. Adv Ther. 2014;31:621-638.
21. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
22. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147-158.
23. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase iii study. Clin Ther. 2014;36:84-100. e109.
24. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
25. Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes Obes Metab. 2017;19:1363-1370.
26. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
27. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18:812-819.
28. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.
29. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl U, Woerle H. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936-948.
30. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087-1095.
31. Strojek K, Yoon K-H, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5:267-283.
32. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;75:323-334.
33. Wilding J, Woo V, Soler N, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-415.
34. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1812389. [Epub ahead of print].
35. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016-1027.
36. Johnsson K, Ptaszynska A, Schmitz B, Sugg J, Parikh S, List J. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:473-478.
37. Dekkers C, Petrykiv S, Laverman G, Cherney D, Gansevoort R, Heerspink H. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20:1988-1993.
38. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-2576.
39. Kalaitzidis RG, Bakris GL. Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk. Curr Vasc Pharmacol. 2010;8:604-611.
40. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777.
41. Dekkers C, Gansevoort R, Heerspink H. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep. 2018;18:27.
42. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes. Endocr Rev. 2011;32:515-531.
43. Xu L, Nagata N, Nagashimada M, et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine. 2017;20:137-149.
44. Coughlan Melinda T, Nguyen T-V, Penfold Sally A, et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci. 2016;130:711-720.
45. Gilbert R. SGLT2 inhibitors: β blockers for the kidney? Lancet Diabetes Endocrinol. 2016;4:814.
46. Puckrin R, Saltiel MP, Reynier P, Azoulay L, OHY Y, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503-514.
47. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes. Australas Med J. 2014;7:405-415.
48. Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12:751-759.
49. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119-129.